Stock Events

Puma Biotechnology 

$3.59
42
+$0.15+4.36% Friday 20:00

Statistics

Day High
3.68
Day Low
3.46
52W High
7.73
52W Low
2.13
Volume
458,735
Avg. Volume
719,783
Mkt Cap
173.18M
P/E Ratio
11.16
Dividend Yield
-
Dividend
-

Earnings

2MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.22
-0.05
0.13
0.3
Expected EPS
-0.22
Actual EPS
-0.05

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBYI. It's not an investment recommendation.
Alphabet
67861
GOOGL
Apple
59769
AAPL
Microsoft
55761
MSFT
Amazon
51133
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Roche
RHHBY
Mkt Cap191.27B
Roche Holding AG competes in the oncology market, directly challenging Puma Biotechnology's cancer-focused treatments.
Astrazeneca
AZN
Mkt Cap239.79B
AstraZeneca operates in similar therapeutic areas as Puma, including breast cancer treatments, making them direct competitors.
Pfizer
PFE
Mkt Cap158.95B
Pfizer has a broad oncology portfolio that includes breast cancer treatments, competing with Puma's neratinib.
Novartis
NVS
Mkt Cap236.8B
Novartis offers treatments in the oncology sector, including breast cancer, directly competing with Puma's offerings.
Merck &
MRK
Mkt Cap320.27B
Merck's extensive research and development in oncology, including breast cancer treatments, positions them as a competitor.
Gilead Sciences
GILD
Mkt Cap83.09B
Gilead Sciences, with its growing oncology portfolio, competes in the same market as Puma Biotechnology.
Bristol-Myers Squibb
BMY
Mkt Cap80.39B
Bristol Myers Squibb's focus on cancer drugs, including breast cancer, makes it a competitor to Puma.
AMGEN
AMGN
Mkt Cap166.77B
Amgen's oncology and hematology portfolio includes treatments that compete with Puma's cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap111.64B
Regeneron Pharmaceuticals, known for its innovative treatments, competes in the oncology space with Puma.
Johnson & Johnson
JNJ
Mkt Cap352.53B
Johnson & Johnson, through its pharmaceutical division Janssen, offers oncology treatments that rival Puma's products.

Analyst Ratings

7$Average Price Target
The highest estimate is $7.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Show more...
CEO
Employees
185
Country
US
ISIN
US74587V1070

Listings

XNAS
US
PBYI